MEA Fibrotic Diseases Treatment Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Middle East and Africa fibrotic diseases treatment market is projected to register a substantial CAGR of 6.0%in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Middle East and Africa Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Bahrain Israel, Rest of Middle East and Africa)

Some of the major factors contributing to the growth of the Middle East and Africa fibrotic diseases treatment market are:

Technological advancement in the treatment of fibrosis diseases

Increase in the number of people smoking cigarettes

Market Players:

Some of the key market players in the Middle East and Africa fibrotic diseases treatment market are listed below:

Boehringer Ingelheim International GmbH

AbbVie Inc.

Bristol-Myers Squibb Company

BioMX

Gilead Sciences, Inc.

Teva Pharmaceutical Industries Ltd.

Sandoz International GmbH

1 INTRODUCTION 33

1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35

2 MARKET SEGMENTATION 37

2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 TREATMENT TYPE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET END USER COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48

3 EXECUTIVE SUMMARY 49

4 PREMIUM INSIGHTS 51

4.1 PORTER'S 5 FORCES 52
4.2 PESTEL ANALYSIS 53

5 EPIDEMIOLOGY 54

5.1 INCIDENCE OF ALL BY GENDER 54
5.2 TREATMENT RATE 54
5.3 MORTALITY RATE 54
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 55
5.5 PATIENT TREATMENT SUCCESS RATE 55

6 INDUSTRY INSIGHTS 56

6.1 PATENT ANALYSIS 56
6.2 DRUG TREATMENT RATE BY MATURED MARKETS 56
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 56
6.4 KEY PRICING STRATEGIES 57
6.5 KEY PATIENT ENROLLMENT STRATEGIES 58

7 MERGERS AND ACQUISITIONS 60

7.1 LICENSING: 60
7.2 COMMERCIALIZATION AGREEMENTS 60

8 PIPELINE ANALYSIS 61

8.1 PHASE 1 61
8.2 PHASE 2 61
8.3 PHASE 3 61

9 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 62

9.1 FDA APPROVALS 62
9.2 EMA APPROVALS 63

10 MARKET OVERVIEW 64

10.1 DRIVERS 66
- 10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 66
- 10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 66
- 10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 67
10.2 RESTRAINTS 67
- 10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 67
- 10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 67
10.3 OPPORTUNITIES 68
- 10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 68
- 10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 68
10.4 CHALLENGES 69
- 10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 69
- 10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 69

11 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 70

11.1 OVERVIEW 71
11.2 MEDICATION 73
- 11.2.1 INTEDANIB (OFEV) 74
- 11.2.2 PIRFENIDONE (ESBRIET) 74
11.3 ORGAN TRANSPLANTATION 74
11.4 OXYGEN THERAPY 75
11.5 OTHERS 76

12 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 77

12.1 OVERVIEW 78
12.2 IDIOPATHIC PULMONARY FIBROSIS 81
12.3 HEPATIC CIRRHOSIS 81
12.4 RENAL FIBROSIS 82
12.5 CUTANEOUS FIBROSIS 83
12.6 OTHERS 84

13 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER 85

13.1 OVERVIEW 86
13.2 HOSPITALS 89
13.3 SPECIALTY CLINICS 90
13.4 ACADEMIC AND RESEARCH INSTITUTES 90
13.5 OTHERS 91

14 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 92

14.1 OVERVIEW 93
14.2 HOSPITAL PHARMACY 96
14.3 RETAIL PHARMACY 96
14.4 OTHERS 97

15 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY REGION 98

15.1 MIDDLE EAST AND AFRICA 99
- 15.1.1 SOUTH AFRICA 105
- 15.1.2 SAUDI ARABIA 107
- 15.1.3 U.A.E 109
- 15.1.4 EGYPT 111
- 15.1.5 KUWAIT 113
- 15.1.6 ISRAEL 115
- 15.1.7 BAHRAIN 117
- 15.1.8 REST OF MIDDLE EAST AND AFRICA 119

16 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 120

16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 120

17 SWOT ANALYSIS 121

18 COMPANY PROFILE 122

18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 122
- 18.1.1 COMPANY SNAPSHOT 122
- 18.1.2 REVENUE ANALYSIS 122
- 18.1.3 COMPANY SHARE ANALYSIS 123
- 18.1.4 PRODUCT PORTFOLIO 123
- 18.1.5 RECENT DEVELOPMENTS 123
18.2 GENENTECH, INC. 124
- 18.2.1 COMPANY SNAPSHOT 124
- 18.2.2 COMPANY SHARE ANALYSIS 124
- 18.2.3 PRODUCT PORTFOLIO 125
- 18.2.4 RECENT DEVELOPMENTS 125
18.3 SANDOZ INTERNATIONAL GMBH 126
- 18.3.1 COMPANY SNAPSHOT 126
- 18.3.2 COMPANY SHARE ANALYSIS 126
- 18.3.3 PRODUCT PORTFOLIO 127
- 18.3.4 RECENT DEVELOPMENTS 127
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 128
- 18.4.1 COMPANY SNAPSHOT 128
- 18.4.2 REVENUE ANALYSIS 128
- 18.4.3 COMPANY SHARE ANALYSIS 129
- 18.4.4 PRODUCT PORTFOLIO 129
- 18.4.5 RECENT DEVELOPMENTS 129
18.5 ACCORD HEALTHCARE U.S. 130
- 18.5.1 COMPANY SNAPSHOT 130
- 18.5.2 COMPANY SHARE ANALYSIS 130
- 18.5.3 PRODUCT PORTFOLIO 131
- 18.5.4 RECENT DEVELOPMENTS 131
18.6 ABBVIE INC. 132
- 18.6.1 COMPANY SNAPSHOT 132
- 18.6.2 REVENUE ANALYSIS 132
- 18.6.3 PRODUCT PORTFOLIO 133
- 18.6.4 RECENT DEVELOPMENTS 133
18.7 ALPINE IMMUNE SCIENCES 134
- 18.7.1 COMPANY SNAPSHOT 134
- 18.7.2 REVENUE ANALYSIS 134
- 18.7.3 PRODUCT PORTFOLIO 135
- 18.7.4 RECENT DEVELOPMENTS 135
18.8 BELLBROOK LABS 136
- 18.8.1 COMPANY SNAPSHOT 136
- 18.8.2 PRODUCT PORTFOLIO 136
- 18.8.3 RECENT DEVELOPMENTS 136
18.9 BIOMX 137
- 18.9.1 COMPANY SNAPSHOT 137
- 18.9.2 REVENUE ANALYSIS 137
- 18.9.3 PRODUCT PORTFOLIO 138
- 18.9.4 RECENT DEVELOPMENTS 138
18.10 BRISTOL-MYERS SQUIBB COMPANY 139
- 18.10.1 COMPANY SNAPSHOT 139
- 18.10.2 REVENUE ANALYSIS 139
- 18.10.3 PRODUCT PORTFOLIO 140
- 18.10.4 RECENT DEVELOPMENTS 140
18.11 CAMBER PHARMACEUTICALS, INC. 141
- 18.11.1 COMPANY SNAPSHOT 141
- 18.11.2 PRODUCT PORTFOLIO 141
- 18.11.3 RECENT DEVELOPMENTS 141
18.12 ENVEDA 142
- 18.12.1 COMPANY SNAPSHOT 142
- 18.12.2 PRODUCT PORTFOLIO 142
- 18.12.3 RECENT DEVELOPMENTS 142
18.13 GILEAD SCIENCES, INC. 143
- 18.13.1 COMPANY SNAPSHOT 143
- 18.13.2 REVENUE ANALYSIS 143
- 18.13.3 PRODUCT PORTFOLIO 144
- 18.13.4 RECENT DEVELOPMENTS 144
18.14 INTERCEPT PHARMACEUTICALS, INC. 145
- 18.14.1 COMPANY SNAPSHOT 145
- 18.14.2 REVENUE ANALYSIS 145
- 18.14.3 PRODUCT PORTFOLIO 146
- 18.14.4 RECENT DEVELOPMENTS 146
18.15 KITHER BIOTECH S.R.L. 147
- 18.15.1 COMPANY SNAPSHOT 147
- 18.15.2 PRODUCT PORTFOLIO 147
- 18.15.3 RECENT DEVELOPMENTS 147
18.16 PHARMAXIS LTD 148
- 18.16.1 COMPANY SNAPSHOT 148
- 18.16.2 REVENUE ANALYSIS 148
- 18.16.3 PRODUCT PORTFOLIO 149
- 18.16.4 RECENT DEVELOPMENTS 149
18.17 REDX PHARMA PLC. 150
- 18.17.1 COMPANY SNAPSHOT 150
- 18.17.2 REVENUE ANALYSIS 150
- 18.17.3 PRODUCT PORTFOLIO 151
- 18.17.4 RECENT DEVELOPMENTS 151
18.18 VERONA PHARMA PLC 152
- 18.18.1 COMPANY SNAPSHOT 152
- 18.18.2 REVENUE ANALYSIS 152
- 18.18.3 PRODUCT PORTFOLIO 153
- 18.18.4 RECENT DEVELOPMENTS 153

19 QUESTIONNAIRE 154

20 RELATED REPORTS 157

LIST OF TABLES

TABLE 1 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, PIPELINE ANALYSIS 44
TABLE 2 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 56
TABLE 3 MIDDLE EAST & AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 57
TABLE 4 MIDDLE EAST & AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 57
TABLE 5 MIDDLE EAST & AFRICA ORGAN TRANSPLANTATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 58
TABLE 6 MIDDLE EAST & AFRICA OXYGEN THERAPY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 59
TABLE 7 MIDDLE EAST & AFRICA OTHER IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 59
TABLE 8 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 63
TABLE 9 MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 64
TABLE 10 MIDDLE EAST & AFRICA HEPATIC CIRRHOSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 65
TABLE 11 MIDDLE EAST & AFRICA RENAL FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 12 MIDDLE EAST & AFRICA CUTANEOUS FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 13 MIDDLE EAST & AFRICA OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
TABLE 14 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 71
TABLE 15 MIDDLE EAST & AFRICA HOSPITALS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 72
TABLE 16 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
TABLE 17 MIDDLE EAST & AFRICA ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
TABLE 18 MIDDLE EAST & AFRICA OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
TABLE 19 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 78
TABLE 20 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
TABLE 21 MIDDLE EAST & AFRICA RETAIL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
TABLE 22 MIDDLE EAST & AFRICA OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
TABLE 23 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 86
TABLE 24 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 86
TABLE 25 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 86
TABLE 26 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 86
TABLE 27 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 87
TABLE 28 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 87
TABLE 29 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 87
TABLE 30 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 87
TABLE 31 SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 88
TABLE 32 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 88
TABLE 33 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 88
TABLE 34 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 88
TABLE 35 SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 89
TABLE 36 SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 89
TABLE 37 SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 89
TABLE 38 SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 90
TABLE 39 SAUDI ARABIA PRODUCTS, 2021-2030 (USD THOUSAND) 90
TABLE 40 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 90
TABLE 41 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 90
TABLE 42 SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 91
TABLE 43 SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 91
TABLE 44 SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 91
TABLE 45 U.A.E FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 92
TABLE 46 U.A.E MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 92
TABLE 47 U.A.E MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 92
TABLE 48 U.A.E MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 92
TABLE 49 U.A.E FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 93
TABLE 50 U.A.E FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 93
TABLE 51 U.A.E FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 93
TABLE 52 EGYPT FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 94
TABLE 53 EGYPT MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 94
TABLE 54 EGYPT MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 94
TABLE 55 EGYPT MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 94
TABLE 56 EGYPT FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 95
TABLE 57 EGYPT FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 95
TABLE 58 EGYPT FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 95
TABLE 59 KUWAIT FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 96
TABLE 60 KUWAIT MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 96
TABLE 61 KUWAIT MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 96
TABLE 62 KUWAIT MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 96
TABLE 63 KUWAIT FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 97
TABLE 64 KUWAIT FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 97
TABLE 65 KUWAIT FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 97
TABLE 66 ISRAEL FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 98
TABLE 67 ISRAEL MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 98
TABLE 68 ISRAEL MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 98
TABLE 69 ISRAEL MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 98
TABLE 70 ISRAEL FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 99
TABLE 71 ISRAEL FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 99
TABLE 72 ISRAEL FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 99
TABLE 73 BAHRAIN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 100
TABLE 74 BAHRAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 100
TABLE 75 BAHRAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 100
TABLE 76 BAHRAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 100
TABLE 77 BAHRAIN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 101
TABLE 78 BAHRAIN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 101
TABLE 79 BAHRAIN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 101
TABLE 80 REST OF MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 102

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: SEGMENTATION 19
FIGURE 2 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: DATA TRIANGULATION 22
FIGURE 3 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: DROC ANALYSIS 23
FIGURE 4 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 24
FIGURE 5 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 24
FIGURE 6 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 26
FIGURE 7 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: DBMR MARKET POSITION GRID 27
FIGURE 8 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: MARKET END USER COVERAGE GRID 28
FIGURE 9 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET : VENDOR SHARE ANALYSIS 29
FIGURE 10 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: SEGMENTATION 32
FIGURE 11 RISING PREVALENCE OF FIBROTIC DISEASES IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET GROWTH IN THE FORECAST PERIOD 33
FIGURE 12 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET IN 2023 & 2030 33
FIGURE 13 PATIENT FLOW DIAGRAM 41
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET 47
FIGURE 15 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT 2022 53
FIGURE 16 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT 2023-2030 (USD THOUSAND) 54
FIGURE 17 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT CAGR (2023-2030) 54
FIGURE 18 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT LIFELINE CURVE 55
FIGURE 19 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, 2022 60
FIGURE 20 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND) 61
FIGURE 21 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, CAGR (2023-2030) 61
FIGURE 22 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE 62
FIGURE 23 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY END USER, 2022 68
FIGURE 24 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 69
FIGURE 25 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY END USER, CAGR (2023-2030) 69
FIGURE 26 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY END USER, LIFELINE CURVE 70
FIGURE 27 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 75
FIGURE 28 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 76
FIGURE 29 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 76
FIGURE 30 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 77
FIGURE 31 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET: SNAPSHOT (2022) 82
FIGURE 32 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022) 83
FIGURE 33 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2023 & 2030) 83
FIGURE 34 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022 & 2030) 84
FIGURE 35 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET: TREATMENT (2023-2030) 84
FIGURE 36 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: COMPANY SHARE 2022 (%) 102